Success Metrics

Active Trials

8(62%)

Phase Distribution

Ph phase_3

Ph phase_2

54%

Ph not_applicable

Ph phase_1

23%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

3(25.0%)

Phase 2Efficacy & side effects

7(58.3%)

Phase 3Large-scale testing

1(8.3%)

N/ANon-phased studies

1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(12)

Terminated(1)

Detailed Status

Recruiting8

Not yet recruiting3

Withdrawn1

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 13 (25.0%)

Phase 27 (58.3%)

Phase 31 (8.3%)

N/A1 (8.3%)

Trials by Status

withdrawn18%

enrolling_by_invitation18%

not_yet_recruiting323%

recruiting862%

Recent Activity

8 active trials

Showing 5 of 13

withdrawnphase_2

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

NCT07134556

recruitingphase_2

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

NCT06682728

recruitingphase_3

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834

recruitingphase_1

Saci Nivo Rela for TNBC

NCT06963905

not_yet_recruitingphase_2

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

NCT07367178

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT07134556Phase 2

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Withdrawn

NCT06682728Phase 2

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Recruiting

NCT06801834Phase 3

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Recruiting

NCT06963905Phase 1

Saci Nivo Rela for TNBC

Recruiting

NCT07367178Phase 2

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Not Yet Recruiting

NCT07359404Phase 2

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Enrolling By Invitation

NCT07299409Phase 2

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Not Yet Recruiting

NCT07251868

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Recruiting

NCT04724018Phase 1

Sacituzumab Govitecan Plus EV in Metastatic UC

Recruiting

NCT06827613Phase 1

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Recruiting

NCT07040644Phase 2

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not Yet Recruiting

NCT07046455Not Applicable

Trop-2 Targeted PET Probes in Advanced TNBC

Recruiting

NCT06243393Phase 2

Sacituzumab Govitecan in Metastatic Colorectal Cancer

Recruiting

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13